Covered recipient · General Payments record
KASHIF ALI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$133,301.27
246 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,188.50 | 36 |
| Consulting Fee | $26,547.50 | 19 |
| Travel and Lodging | $6,203.29 | 9 |
| Food and Beverage | $4,362.99 | 165 |
| Honoraria | $1,650.00 | 1 |
| Long term medical supply or device loan | $1,031.22 | 11 |
| Education | $317.77 | 5 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KASHIF ALI
NPI 1851423388 · CMS profile ID 310504
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SILVER SPRING, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KASHIF ALI, NPI 1851423388, CMS profile ID 310504. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). KASHIF ALI, NPI 1851423388, CMS profile ID 310504. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- KASHIF ALI, NPI 1851423388, CMS profile ID 310504, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
246 matching records · $133,301.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 246.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BeiGene, Ltd. | $525.00 | 10/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846701631 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 10/16/2021 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583521 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.88 | 10/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404325 | CMS |
| Celgene Corporation | $21.98 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783670167 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,635.00 | 10/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404367 | CMS |
| Myriad Genetic Laboratories, Inc. | $12.35 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834554943 | CMS |
| Exelixis Inc. | $20.09 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838872511 | CMS |
| Incyte Corporation | $24.37 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835555251 | CMS |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 10/06/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404377 | CMS |
| Janssen Pharmaceuticals, Inc | $7.93 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750845 | CMS |
| Merck Sharp & Dohme Corporation | $15.91 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848690121 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.05 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404335 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 10/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404341 | CMS |
| Amgen Inc. | $21.44 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826372441 | CMS |
| Myriad Genetic Laboratories, Inc. | $74.95 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834554939 | CMS |
| E.R. Squibb & Sons, L.L.C. | $82.16 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404351 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,059.05 | 09/29/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404353 | CMS |
| GENZYME CORPORATION | $16.16 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843594843 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404329 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $20.44 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834088873 | CMS |
| AbbVie Inc. | $23.50 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793850809 | CMS |
| ARRAY BIOPHARMA INC | $14.73 | 09/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833183671 | CMS |
| Daiichi Sankyo Inc. | $20.99 | 09/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836322237 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 09/16/2021 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583519 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.70 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809554691 | CMS |
| PFIZER INC. | $21.35 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832841591 | CMS |
| PFIZER INC. | $13.17 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832870941 | CMS |
| TG THERAPEUTICS, INC. | $24.90 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844043041 | CMS |
| Janssen Biotech, Inc. | $26.82 | 09/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750827 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.19 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783404313 | CMS |
| Janssen Biotech, Inc. | $7.21 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750833 | CMS |
| Janssen Biotech, Inc. | $8.76 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750835 | CMS |
| Novartis Pharmaceuticals Corporation | $18.06 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583497 | CMS |
| Janssen Biotech, Inc. | $1,560.00 | 08/30/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750825 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $29.75 | 08/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781007651 | CMS |
| Amgen Inc. | $20.31 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826372437 | CMS |
| GENZYME CORPORATION | $14.96 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843594825 | CMS |
| GENZYME CORPORATION | $14.92 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843594829 | CMS |
| Janssen Biotech, Inc. | $1,160.00 | 08/18/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788750831 | CMS |
| Secura Bio, Inc. | $18.63 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851659277 | CMS |
| Tactile Systems Technology Inc | $14.92 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 757097192 | CMS |
| Novartis Pharmaceuticals Corporation | $18.96 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583499 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 08/16/2021 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583517 | CMS |
| Seagen Inc. | $95.00 | 08/16/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832149395 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.51 | 08/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783113369 | CMS |
| Novartis Pharmaceuticals Corporation | $24.07 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583495 | CMS |
| Merck Sharp & Dohme Corporation | $13.79 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848375661 | CMS |
| Secura Bio, Inc. | $40.11 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 851659273 | CMS |
| GENZYME CORPORATION | $14.69 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843594801 | CMS |
| PFIZER INC. | $18.28 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832615893 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $75,711.75 | 48 |
| PY2024 | Principal investigator | $78,113.05 | 29 |
| PY2023 | Principal investigator | $31,721.46 | 66 |
| PY2022 | Recipient | $13,000.00 | 18 |
| PY2022 | Principal investigator | $70,583.15 | 17 |
| PY2021 | Principal investigator | $93,784.00 | 13 |
| PY2020 | Principal investigator | $8,500.00 | 2 |
| PY2019 | Principal investigator | $200.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
48 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 12/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740484 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 11/30/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740482 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742522 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,275.00 | 10/31/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185539049 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740480 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742517 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742519 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742515 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 09/30/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740462 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 08/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740464 |
| Principal investigator 1 | Amgen Inc. | $33.34 | 08/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | No dispute reported | 06/30/2026 | 1246643838 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942189 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942214 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942277 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942291 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742509 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742511 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742513 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 07/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740466 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942226 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 06/30/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740468 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942239 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942253 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 05/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740470 |
| Principal investigator 1 | Amgen Inc. | $166.70 | 05/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | MyLung Consortium Study (USOR) | No dispute reported | 06/30/2026 | 1246643842 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,000.00 | 05/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176544953 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942154 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942165 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942267 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942303 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942338 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 04/30/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740472 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742499 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942315 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742501 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 03/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740474 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942177 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742503 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $18,500.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742505 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,500.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742507 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 02/28/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,125.00 | 02/12/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Silver Spg White Oak Ca | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175230394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,125.00 | 02/12/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Silver Spg White Oak Ca | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175230405 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 01/31/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233740478 |
| Principal investigator 1 | AstraZeneca UK Limited | $10,950.00 | 01/27/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy (COMPEL) | No dispute reported | 06/30/2026 | 1185539045 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $520.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185539047 |
| Principal investigator 1 | Eli Lilly and Company | $433.33 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY PA | Not supplied | No dispute reported | 06/30/2026 | 1187885770 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 01/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematlgy Columbia | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942327 |